A

Adaptimmune Therapeutics plc
D

ADAP

0.59970
USD
0.01
(0.84%)
Market Closed
Volume
0
EPS
-0
Div Yield
-
P/E
-4
Market Cap
153,453,159
OverviewSignalsIdeasNews
Related Instruments
    EOSUSD
    EOSUSD
    -0.00365
    (-0.45%)
    0.79969 USD
    E
    EOS
    0.200
    (0.85%)
    23.830 USD
    L
    LINK
    0.61000
    (10.70%)
    6.31000 USD
    T
    TRX
    -0.00880
    (-2.86%)
    0.29880 USD
    More
News

Title: Adaptimmune Therapeutics plc

Sector: Healthcare
Industry: Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.